Beta-adrenergic Blocking Agents: Their Current Status

Clark, Barbara K.

doi:10.4037/15597768-1992-2016

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…β-blockers are increasingly used not only in cardiology but also in other specialties, such as endocrinology, psychiatry, and neurology. Not all the properties of β-blockers have been fully elucidated, and new indications may emerge [1]. Propranolol is a β-adrenergic receptor antagonist discovered by an English researcher, Sir James Black, to treat the symptoms of angina pectoris.…”

Section: Introductionmentioning

confidence: 99%

Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update

Serreau,

Amirouche,

Benyamina

et al. 2024

Oxygen

View full text Add to dashboard Cite

In this review, in addition to the potential cardiovascular applications of β-blockers and, more specifically, propranolol, we wanted to list the more recent applications in psychiatry as well as current knowledge on the impact of oxidative stress on propranolol hydrochloride and the oxidative stress that could be limited by the latter. In fact, a number of studies show that this molecule is modified by oxidative stress but is also able to limit it. Mention is also made to studies on the increasingly important problem of eliminating drug waste and its impact on the environment, particularly the marine environment. Given the increase in the consumption of medicines, more rigorous waste management is needed to avoid impacting biodiversity.

show abstract

Section: Introductionmentioning

confidence: 99%

Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update

Serreau,

Amirouche,

Benyamina

et al. 2024

Oxygen

View full text Add to dashboard Cite

show abstract

Age-Related Changes Affecting Atherosclerotic Risk

et al. 1996

View full text Add to dashboard Cite

The incidence of cardiovascular diseases that are related to the atherosclerotic process increases exponentially with age. Organ lesions, the clinical manifestation of atherosclerotic disease, are late events due to complications in the plaque (ulceration, thrombosis, calcification) which are the result of an increased vulnerability to disruption of a previously stable plaque. The higher incidence of age-related clinical events could be explained by a rising sensitivity of plaques to destabilising factors, both parietal and humoral. The increased probability that a plaque in an elderly patient will became vulnerable could be related to those destabilising factors that significantly increase with aging, such as advanced glycation end-products. For these reasons, it seems most important that the analysis of these age-related destabilising factors, rather than those factors that promote the development of early atherosclerotic plaques, should be undertaken. Taking the point of view of a pharmacological intervention, this should eventually lead to a more complete understanding of this process.

show abstract

Beta-adrenergic Blocking Agents: Their Current Status

Cited by 2 publications

References 0 publications

Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update

Propranolol Hydrochloride Psychiatric Effectiveness and Oxidative Stress: An Update

Age-Related Changes Affecting Atherosclerotic Risk

Contact Info

Product

Resources

About